Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q13370

UPID:
PDE3B_HUMAN

ALTERNATIVE NAMES:
CGIPDE1; Cyclic GMP-inhibited phosphodiesterase B

ALTERNATIVE UPACC:
Q13370; B7ZM37; O00639; Q14408; Q6SEI4

BACKGROUND:
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B, known alternatively as CGIPDE1, serves as a dual-specificity enzyme for cAMP and cGMP, essential regulators of physiological processes. By influencing the RAPGEF3 pathway and PI3K gamma-mediated signaling, it plays a crucial role in angiogenesis and controls cardiac contractility, highlighting its significance in cardiovascular health.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B is key to unlocking new therapeutic avenues. Its critical role in managing cellular signaling pathways presents an opportunity for the development of innovative treatments targeting cardiovascular diseases and disorders related to angiogenesis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.